Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Credit: The Aplastic Anemia and MDS International Foundation


’s new Clinical Practice Guidelines on Diagnosis and Management of Severe and Very Severe Acquired Aplastic Anemia (AA) outline 33 recommendations and 4 good practice statements for children and adults.

The guidelines focus on tools to improve diagnosis and treatment decisions, including expanded use of specialized blood and genetic tests, personalized initial treatment based on age and availability of a fully matched donor, the addition of eltrombopag to standard immunosuppressive therapy to improve blood cell counts, and earlier transition to second-line treatments after initial immunosuppression for patients who do not respond or relapse.

“It’s critical to definitively diagnose individuals with aplastic anemia to ensure that they are promptly connected to appropriate treatment,” said Phil Scheinberg, MD, head of the division of hematology at Hospital Beneficência Portuguesa Hospital in São Paulo, and chair of the ASH 2026 Guidelines for the Diagnosis and Management of Severe and Very Severe Acquired Aplastic Anemia. “We hope these guidelines will not only improve patient outcomes but also expand access to diagnostic testing and catalyze broader global access to transplant and immunosuppressive therapies.”

The rare and serious hematologic disorder, AA, is characterized by the failure of bone marrow to produce enough blood cells, which leads to pancytopenia, a serious blood condition characterized by a deficiency in the cellular components of red blood cells, white blood cells, and platelets. Often, the severe complications of aplastic anemia include profound fatigue, increased susceptibility to infections, and an increased hemorrhage risk.

In the US and Europe, the incidence of acquired AA is 2 to 3 per million people per year, and has increased rates in Asia, reported at 5–6 per million in some regions. At diagnosis, about 79.6% to 83.8% of these patients have severe or very severe disease. If treated with supportive care alone, mortality can be > 80% within 2 years due to severe neutropenia (low neutrophil count) and thrombocytopenia, leading to infection or hemorrhage.

Modern treatment strategies such as allogeneic hematopoietic cell transplantation (alloHCT), stem cell bone marrow transplants, blood transfusions or Immunosuppressive Therapy (IST) have improved these 2-year survival rates to >80%.

To create the guidelines, a multidisciplinary expert panel, including a patient with liver experience, focused on severe cases of acquired aplastic anemia, characterized by especially reduced counts of neutrophils (white blood cells, <500 per microliter), anemia with reduced reticulocytes (immature red blood cells, <60,000 per microliter), and platelets (cells necessary for clotting, <20,000 per microliter) in the blood.

The updated 2026 guidelines included eltombopag, a small molecule thrombopoetin (TPO) mimetic, as a first-line treatment option. It is approved by the 

to treat severe AA in combination with standard immunosuppressive therapy for newly diagnosed adults and pediatric patients ≥2 years of age and for patients who have exhibited an insufficient response to immunosuppressive therapy.

“The Society is proud to provide this robust and much-needed resource for clinicians caring for individuals with aplastic anemia,” said Robert Negrin, MD, ASH president. “These guidelines offer important consensus for the field while helping raise awareness of a serious, yet often overlooked, disorder.”

Scheinberg P, O’Neal DA, Basquiera AL, et al. American Society of Hematology 2026 Guidelines for the Diagnosis and Management of Severe Acquired Aplastic Anemia. Blood Advances. Published March 24, 2026. Accessed April 2, 2026. 

https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025019051/567383/American-Society-of-Hematology-2026-Guidelines-for

Schoettler ML, Nathan DG. The Pathophysiology of Acquired Aplastic Anemia. 

Hematology/Oncology Clinics of North America

https://doi.org/10.1016/j.hoc.2018.03.001

Moore CA, Krishnan K. Aplastic Anemia. PubMed. Published 2022. 

https://pubmed.ncbi.nlm.nih.gov/30480951/

Articles

ASH publishes 33 clinical recommendations and 4 good practice statements for the diagnosis and treatment of severe and very severe acquired aplastic anemia. 

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Hematology

ASH Publishes Guidelines on Diagnosis and Management of Severe and Very Severe Acquired Aplastic Anemia

Professor Stephen Nicholls is a world-renowned cardiologist, and leads the Victorian Heart Hospital (VHH) at Monash University.

BROADWAY: Obicetrapib Preserves Kidney Function, Prevents CKD, With Stephen Nicholls, MD 

 receiving CETP inhibition with obicetrapib saw preserved kidney function in addition to increased HDL-C, according to the recent BROADWAY trial.

American College of Cardiology (ACC) Scientific Sessions 2026

 in New Orleans, Louisiana, by Stephen Nicholls, MD, director of the Monash Velos Accelerator, program director of MonashHeart, Intensive Care and Victorian Heart Hospital, and director of the Monash Victorian Heart Institute at Monash Health.

“What we’re trying to demonstrate is that obicetrapib was effective, and that when added to other lipid-lowering therapy, it will produce effective lowering of LDL cholesterol, which ultimately translates to a reduction in cardiovascular events,” Nicholls told 

 in an exclusive interview. “The main take-home message for clinicians about this analysis is that it adds to the reassuring safety and tolerability profile of obesity.”

Patients with cardiovascular disease face a risk of 

 progression due to HDL-C dysfunction, which has shown an association with CKD in prior research. CETP inhibition reduces cardiovascular risk by raising HDL-C, which experts believed could benefit HDL production and protect kidney health. To judge the veracity of this, investigators conducted the BROADWAY trial.

BROADWAY was a multinational, double-blind, placebo-controlled trial including patients with either heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD). Patients were excluded if they had New York Heart Association class III or IV heart failure, left ventricular ejection fraction <30%, major adverse cardiac events within 3 months of screening, uncontrolled severe hypertension, or a formal diagnosis of homozygous familial hypercholesterolemia, among other criteria. A total of 2530 patients were included and randomly assigned to either obicetrapib 10 mg daily or placebo for 365 days.

Among the included patients, all were on maximally tolerated lipid-lowering therapy during the trial. Baseline demographics, blood pressure, and concomitant renoprotective medications (including ACE inhibitors, ARBs, and SGLT2 inhibitors) were all well-balanced, and investigators noted their stability throughout the study duration. Renal function was assessed throughout the full study period.

At baseline, participants had eGFR 84.2 +/- 18 mL/min/1.73 m

 and a median albumin-to-creatinine ratio of 11 mg/g. Over the course of the study, obicetrapib attenuated kidney function decline compared to placebo; annualized eGFR decline was 0.27 mL/min/1.73 m

 with obicetrapib versus 1.19 mL/min/1.73 m

 with placebo (difference 0.92 mL/min/1.73 m

 = .023). Additionally, progression to advanced CKD, which was defined as eGFR <30 mL/min/1.73 m

, occurred in 0.8% of patients versus 1.5% of placebo patients.

Nicholls and colleagues noted moderate eGFR decline (≥25%) in 6.8% of patients in the obicetrapib arm compared to 8.3% in the placebo arm. Albuminuria progression was also lower with obicetrapib (+9 mg/g versus +13.8 mg/g with placebo). Ultimately, no patients required dialysis or kidney transplantation during follow-up.

“We observed no deleterious effects on kidney function with obicetrapib, which is a very reassuring finding, and gives us more hope as we move forward in larger studies in the development program,” Nicholls said. “These findings are important for the practicing clinician in terms of the reassuring safety and tolerability of this agent.”

Editors’ Note: Nicholls reports disclosures with AstraZeneca, NewAmsterdam Pharma, Amgen, Omthera, Merck, Boehringer Ingelheim, and others.

Vogt L, Davidson M, Kling D, et al. CETP Inhibition With Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results from the BROADWAY Trial. Abstract presented at the American College of Cardiology Scientific Sessions 2026, New Orleans, LA. March 28-30, 2026.

NewAmsterdam Pharma. Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY). ClinicalTrials.gov Identifier: NCT05142722. Updated September 19, 2025. Accessed April 2, 2026. 

https://clinicaltrials.gov/study/NCT05142722

Videos

Nicholls discusses the investigational oral CETP inhibitor’s effects on kidney health for patients at high risk of cardiovascular disease due to elevated HDL-C.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Strategic Alliance Partnership

Marcello Tonelli, MD, is a nephrologist and professor of medicine at the University of Calgary, founding director of the World Health Organization Collaborating Centre on Prevention and Control of Chronic Kidney Disease, and president of the International Society of Nephrology.

Global Kidney Health: Key Takeaways From the WHO Resolution

Chronic kidney disease has long been underrecognized on the global health stage, despite affecting hundreds of millions of people worldwide. A new resolution from the World Health Organization at the 78th World Health Assembly aims to change that, elevating kidney disease alongside other major noncommunicable diseases and signaling a shift toward more coordinated, large-scale action.

According to Marcello Tonelli, MD, MSc, a nephrologist and professor of medicine at the University of Calgary, founding director of the World Health Organization Collaborating Centre on Prevention and Control of Chronic Kidney Disease, and president of the International Society of Nephrology, the significance of this resolution lies in its acknowledgment that kidney disease is common, preventable, treatable, and deadly. For the first time, it is being positioned alongside conditions such as hypertension, diabetes, and cardiovascular disease on the global policy agenda.

“We know from experience that if you can mobilize efforts behind resolution, drive implementation, you can get action that benefits millions of people,” he said.

From a clinical perspective, the resolution places strong emphasis on early detection and the integration of kidney care into primary care settings. Tonelli underscores that the current nephrology workforce alone cannot meet the needs of the estimated 800 million people living with kidney disease worldwide. Instead, broader collaboration with primary care providers and other specialties will be essential to expanding access to timely diagnosis and treatment.

Beyond the clinical implications, he highlights the importance of health system infrastructure, areas that may receive less attention but are vital for long-term success. Strategic national planning, effective procurement systems, and workforce development are all key components of implementation. While these efforts may take years or even decades to fully realize, they form the foundation for sustainable progress.

Importantly, Tonelli notes that adoption of the resolution will vary across countries, depending on local resources, priorities, and healthcare systems. Core goals, however, remain consistent: improving early detection, expanding access to treatment, and scaling up kidney replacement therapies such as dialysis and transplantation in a way that is appropriate for each setting. Equally critical will be the development of monitoring and evaluation systems to track progress and ensure accountability.

Clinicians, he adds, have a unique role to play in both delivering care and advocating for change. As trusted voices within their communities, they can help raise awareness and influence policy decisions.

Ultimately, the resolution represents an opportunity to reshape kidney care globally, but realizing its full potential will require sustained collaboration across clinical, policy, and public health domains.

“Clinically speaking, the biggest opportunities are going to be with, in my opinion, early detection and timely treatment. We have so many great new drugs, but there are so many people that don't have access to them, finding the people, getting them on the right therapies, and keeping them on therapies for years. We can make a big impact that way,” Tonelli said. “We're going to have to put the systems in place that make that possible, which is going to take a lot of time and a lot of effort.”

Editors’ note: Tonelli reports no relevant disclosures.

ISN. Historic win for kidney health as WHO adopts global resolution. May 23, 2025. Accessed April 2, 2026. 

https://www.theisn.org/blog/2025/05/23/historic-win-for-kidney-health-as-who-adopts-global-resolution/

Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl.. 2022;12(1):7-11. doi:10.1016/j.kisu.2021.11.003

The WHO resolution on kidney health elevates kidney disease as a global health priority, emphasizing early detection, treatment, and system-wide action.

Elevating Kidney Disease in Global Health Policy, With Marcello Tonelli, MD

Rajiv Agarwal, MD, MS, is a Professor Emeritus of Medicine at Indiana University School of Medicine and VA Medical Centre in Indianaoplis.

Who Benefits Most From CKD Combination Therapy? Breaking Down CONFIDENCE Trial Findings

The treatment paradigm for chronic kidney disease (CKD) is rapidly evolving, as clinicians move from a single-drug approach to a more complex, multi-therapy strategy. Over the past several years, the introduction of SGLT2 inhibitors, finerenone, and semaglutide alongside traditional RAAS blockade has created both new opportunities and new uncertainty around how best to deploy these therapies.

In an interview with HCPLive at World Congress of Nephrology (WCN) in Yokohama, Japan, Rajiv Agarwal, MD, MS, said this expanding toolkit has raised a critical question as to whether therapies should be introduced sequentially or started together. While clinicians have historically taken a stepwise approach titrating one agent at a time, he notes that this process can take up to a year, time during which ongoing kidney and cardiovascular damage may continue.

In response, the CONFIDENCE trial was designed to evaluate whether simultaneous initiation of combination therapy could accelerate benefit without compromising safety. He explains that this was the first adequately powered study to assess starting therapies such as finerenone and SGLT2 inhibitors at the same time. While prior studies evaluated add-on strategies, they did not address the safety and efficacy of concurrent initiation.

Concerns going into the trial included the potential for hypotension, acute kidney injury, and hyperkalemia, particularly given the hemodynamic effects of these agents. The findings, however, demonstrated that combination therapy could achieve meaningful reductions in albuminuria both safely and effectively.

A pair of additional analyses from CONFIDENCE presented at WCN offer further insight into patient response. The first examined differences by sex and age, revealing that women experienced approximately 20% greater reductions in urinary albumin-to-creatinine ratio compared with men. Agarwal noted that older patients also demonstrated enhanced responses, with each decade of age associated with a roughly 10% greater likelihood of benefit. Of note, these gains were not accompanied by increased safety concerns, challenging assumptions about treating higher-risk populations.

The second analysis addressed early declines in estimated glomerular filtration rate (eGFR), a common concern when initiating these therapies. Agarwal emphasizes that these initial dips are typically reversible and not predictive of long-term harm. Rather than discontinuing treatment, clinicians should monitor patients closely, particularly if eGFR declines exceed 30%, and adjust contributing factors such as volume status or concomitant medications.

Ultimately, he underscores that multimodal therapy represents the future of CKD management. Early and sustained use of combination treatment, he suggests, has the potential to significantly reduce cardiovascular events and extend patient survival.

Editors’ note: Relevant disclosures for Agarwal include Akebia Therapeutics, Alnylam, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Intercept, Novartis, and others.

Campbell P. CONFIDENCE: SGLT2i and Finerenone Effective, Safe to Initiate Simultaneously in CKD. HCPLive. June 5, 2025. Accessed April 2, 2026. 

https://www.hcplive.com/view/confidence-sglt2i-and-finerenone-effective-safe-to-initiate-simultaneously-in-ckd

Agarwal R. Effect of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-creatinine Ratio by Age and Sex in the CONFIDENCE Trial. Presented at World Congress of Nephrology (WCN) in Yokohama, Japan, March 28-31, 2026.

Agarwal R. Estimated Glomerular Filtration Rate, Systolic Blood Pressure, and Urinary Albumin-to-creatinine Ratio — Unravelling the Interplay in Combination: Findings From the CONFIDENCE Trial. Presented at World Congress of Nephrology (WCN) in Yokohama, Japan, March 28-31, 2026.

Further CONFIDENCE analyses support safe combination therapy in CKD, with improved responses in key patient subgroups.

CONFIDENCE Trial Insights on CKD Combination Therapy, With Rajiv Agarwal, MD, MS

Pranav Garimella, MBBS, MPH, is chief medical officer of the American Kidney Fund.

OPTN Policy Gave Back Time, Increased Transplants for Black Kidney Candidates So Why Have Rates Plateaued?

national policy restored waitlisting time and saw an increase in 5.3 transplants per 1000 listings

 for Black kidney transplant candidates marginalized by race-based kidney function equations for decades.

New data from the Organ Procurement and Transplantation Network (OPTN) pointed out that transplant rates have begun to decline again, with experts suggesting structural barriers remain a looming challenge in getting historically marginalized patients onto transplant lists.

“The numbers for a long period of time have been stable, and we see this fight between 2023 and 2024 and over the last two years, once again, there has been a flattening of that curve, and that's because what the policy did was to repay a historical debt of inequity, and that has now been restored,” Pranav Garimella, MBBS, MPH, Chief Medical Officer of the American Kidney Fund and an associate professor of medicine at UC San Diego, told HCPLive. “The question now remains, how do we take this forward and improve access to transplantation for people who have historically been marginalized?”

The history of race-based GFR involves distinct values for patients who identified as black compared to other races. These were based on studies published in the 1990s, which found increased serum creatinine levels in black participants, which they attributed to increased average muscle mass, a historic clinical misconception and stereotype. As a result, race-based GFR equations systematically assigned a ~16–18% higher eGFR value to these patients, leading to an underestimation in the severity of kidney disease, thereby delaying treatment at crucial intervention windows.

In 2021, the National Kidney Foundation and American Society of Nephrology recommended the 2021 CKD-EPI Creatinine Equation, a race-free formula using serum creatinine, age, and sex, removing the variable “black” or “non-black”. The OPTN implemented a national policy in 2022, bolstering the CKD-EPI equation to improve accuracy and fairness in kidney care.

As recently as January 2023, the OPTN implemented a second national policy, which required the review and adjustment of waiting times for Black candidates who had been disadvantaged by the previous equation.

Despite the gains made by this national policy, 

barriers to kidney care and transplantation remain for historically marginalized patient populations.

“Even if we provide them with an updated GFR that makes them eligible, there are factors, financial economics, and social determinants that may not allow them to receive a transplant,” Garimella said. “While the policy itself has shown that it can result in meaningfully increased transplant access to patients who get to that transplant list, getting to that transplant list remains the challenge, and again, beyond people who identify as black.”

Another important facet of this data that Garimella points out is the increase in transplants for candidates who identified as Black, which did not reduce transplants from individuals of other races. He emphasizes that correcting this historical injustice does not mean taking away from others.

Editor’s Note: Garimella has relevant disclosures with Otsuka and the PKD Foundation.

Khazanchi R, Fleishman A, Eneanya ND, et al. Wait Time Modifications for Black Transplant Candidates Affected by Race-Based Kidney Function Estimation. 

. Published online September 2026:e260001. doi:

https://doi.org/10.1001/jamainternmed.2026.0001

Uppal P, Benjamin Ira Golden, Panicker A, Khan OA, Burday MJ. The Case Against Race-Based GFR. 

https://doi.org/10.32481/djph.2022.08.014

Charles K, Mary Jane Lewis, Montgomery E, Reid M. The 2021 Chronic Kidney Disease Epidemiology Collaboration Race-Free Estimated Glomerular Filtration Rate Equations in Kidney Disease: Leading the Way in Ending Disparities. 

New OPTN data shows kidney transplant gains from race-free GFR and restored wait times stall, as structural barriers still limit equitable listing access.

Michael E. Thase, MD, of the University of Pennsylvania

An interview with Thase explores rapid antidepressant effects and real-world considerations for single-day individualized GH001 dosing in TRD.


Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Single-Day GH001 for TRD Shows Rapid Response, With Michael E. Thase, PhD

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Indirect data suggest oral semaglutide may reduce weight more than orforglipron, but cross-trial comparisons limit clinical interpretation.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Indirect Analysis Suggests Greater Weight Loss With Oral Semaglutide vs Orforglipron

Ackerman offers a broad perspective on how psoriatic treatment is shifting, from oral IL-23 inhibitors to the emerging role of incretin therapy in psoriatic disease.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

AAD 2026: Owning Psoriatic Disease, With Lindsay Ackerman, MD

Experts examine CSU endotypes and their implications for treatment selection and preview the emerging therapeutic pipeline including barzolvolimab and novel mast cell–depleting strategies.

Disease Mechanisms, Emerging Therapies, and Reducing Corticosteroid Reliance in CSU 

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

The durability of both skin clearance and itch reduction extended up to 4 years of lebrikizumab use in this assessment of adults and adolescents with atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Lebrikizumab for Atopic Dermatitis Leads to 4 Years of Clearance, Itch Reduction

Podcasts

Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.

ABCs in Dermatology

Welcome to ABC’s in Dermatology, HCPLive’s newest dermatology podcast, hosted by a pair of the field’s leading minds in Lindsay Ackerman, MD, and Chris Bunick, MD, PhD.

Created by the same team behind The Medical Sisterhood and Skin of Color Savvy, ABCs in Dermatology is a monthly podcast designed to deliver candid conversations, clinical insight, and forward-looking perspectives from the voices shaping dermatology today.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

ABCs in Dermatology: Late Breaking Data Spotlight at AAD 2026

Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

54-week data from the phase 3 STOP-HS1 and STOP-HS2 trials demonstrate JAK inhibitor povorcitinib's benefit in HS.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Povorcitinib Delivers Deepening Responses Through 54 Weeks in Moderate-to-Severe HS, With Martina Porter, MD

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

New IgAN guidelines emphasize earlier diagnosis, lower proteinuria targets, and combination therapy to delay kidney failure and improve long-term outcomes.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Rethinking When and How to Treat IgA Nephropathy, With Sayna Norouzi, MD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

This episode addresses the groundbreaking approval of the first GLP-1 RA without timing or meal restrictions.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Diabetes Dialogue: Orforglipron Receives FDA Approval for Chronic Weight Management

Martinez discusses the bigger picture of mavacamten, highlighting its safety and efficacy as well as recent real-world trial data in patients with HCM.

Latest News

ASH Publishes Guidelines on Diagnosis and Management of Severe and Very Severe Acquired Aplastic Anemia

BROADWAY: Obicetrapib Preserves Kidney Function, Prevents CKD, With Stephen Nicholls, MD

Elevating Kidney Disease in Global Health Policy, With Marcello Tonelli, MD

CONFIDENCE Trial Insights on CKD Combination Therapy, With Rajiv Agarwal, MD, MS

OPTN Policy Gave Back Time, Increased Transplants for Black Kidney Candidates So Why Have Rates Plateaued?